Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Crohn’s Disease

- PMLiVE

Eli Lilly’s GIP/GLP-1 receptor agonist tirzepatide shows promise in fatty liver disease MASH

Metabolic dysfunction-associated steatohepatitis is the second most common contributor to liver transplantation in the US

- PMLiVE

Eli Lilly’s Alzheimer’s drug unanimously endorsed by FDA panel of experts

The company is seeking approval of donanemab to treat patients with early stages of the disease

- PMLiVE

Researchers identify new major cause of inflammatory bowel disease

Crohn’s disease and ulcerative colitis affected more than 500,000 people in the UK in 2022

- PMLiVE

Eli Lilly gains rights to QurAlis’ neurodegenerative disease therapy in deal worth over $620m

The agreement gives the company global rights to QRL-204 and other UNC13A-targeting compounds

- PMLiVE

Eli Lilly commits further $6.5m to UNICEF for young people at risk of noncommunicable diseases

The new funding builds on the company’s initial commitment of $14.4m in 2022

- PMLiVE

Eli Lilly to invest additional $5.3bn totalling $9bn in US manufacturing sites

The investment will provide an additional 200 jobs and more than 5,000 construction jobs during development of the site

- PMLiVE

New study aims to identify IBD biomarkers for personalised medicine

The chronic gastrointestinal condition affects more than 540,000 people in the UK

- PMLiVE

Eli Lilly shares positive late-stage results for mirikizumab in Crohn’s disease

Nearly one in every 100 people in the US are diagnosed with inflammatory bowel disease

- PMLiVE

Eli Lilly and Aktis enter $1bn partnership to develop anticancer radiopharmaceuticals

Lilly will gain rights to develop Aktis’ lead programme targeting a tumour-associated antigen

- PMLiVE

Johnson & Johnson shares positive phase 3 results for Tremfya versus Stelara in Crohn’s disease

The GALAXI programme comprises three trials evaluating the IL-23 inhibitor in the IBD condition

- PMLiVE

Eli Lilly shares promising phase 3 results for once-weekly insulin efsitora in type 2 diabetes

It is hoped that a once-weekly treatment option could lead to improved adherence

- PMLiVE

Takeda’s subcutaneous Entyvio approved by FDA as Crohn’s disease maintenance therapy

Inflammatory bowel disease affects around ten million people worldwide

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links